CD19.CAR T cells versus obinutuzumab - who will win the race for use in deep B cell depletion therapy in systemic autoimmunity?
Over recent months, a number of noteworthy case reports and small case series have reported safety and unprecedented efficacy for CD19-targeting Chimeric Antigen Receptor (CAR) T cell therapy in various severe and refractory autoimmune diseases. A new milestone in innovative, cell-based treatment in...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
09 March 2024
|
| In: |
Rheumatology
Year: 2024, Volume: 63, Issue: 9, Pages: 2317-2318 |
| ISSN: | 1462-0332 |
| DOI: | 10.1093/rheumatology/keae144 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1093/rheumatology/keae144
|
| Author Notes: | Peter Kvacskay and Wolfgang Merkt |
| Summary: | Over recent months, a number of noteworthy case reports and small case series have reported safety and unprecedented efficacy for CD19-targeting Chimeric Antigen Receptor (CAR) T cell therapy in various severe and refractory autoimmune diseases. A new milestone in innovative, cell-based treatment in systemic autoimmunity is on the horizon. Treatment with CD19-targeting CAR T cells is now an established therapy in haematology, and it is increasingly being suggested for the treatment of various non-malignant diseases [1]. The first use of anti-CD19.CAR T cells in rheumatology was in a patient affected by severe SLE, and significant clinical and serological improvement was observed after the treatment [2]. |
|---|---|
| Item Description: | Gesehen am 09.08.2024 |
| Physical Description: | Online Resource |
| ISSN: | 1462-0332 |
| DOI: | 10.1093/rheumatology/keae144 |